不同剂量瑞舒伐他汀对冠心病介入治疗患者血脂的影响分析

Effect of different dosage of rosuvastatin on blood lipid in patients with coronary heart disease intervention therapy

目的研究分析冠心病介入治疗术后不同瑞舒伐他汀剂量对血脂的影响。方法随机选取2017年4月-2018年4月本院收治的120例行介入治疗的冠心病患者作为研究的对象。根据随机原则分为甲、乙、丙三组,每组40例,给予甲组患者实施常规治疗,乙、丙两组分别联合瑞舒伐他汀5 mg/d、10 mg/d进行治疗,观察介入治疗术后不同瑞舒伐他汀剂量对血脂影响及安全性。结果治疗后,乙、丙两组患者的TC、LDL-C治疗效果均优于甲组及治疗前,差异有统计学意义(P<0.05)。三组患者的TG、HDL-C水平与治疗前相比无明显变化,差异无统计学意义(P>0.05)。乙、丙组两组患者缺血事件的发生率均低于甲组,差异有统计学意义(P<0.05)。乙组患者不良反应发生率高于甲组,比较差异无统计学意义(P>0.05);丙组不良反应发生率均高于甲组,差异有统计学意义(P<0.05)。结论应用瑞舒伐他汀对行介入治疗后的冠心病患者进行治疗,可有效改善患者的TC、LDL-C水平,降低缺血事件的发生率;随着瑞舒伐他汀剂量的增加,对患者血脂变化的影响也越大,同时也增加了不良反应的发生风险。

Objective To study the effect of different doses of rosuvastatin on blood lipid after coronary interventional therapy. Methods A total of 120 patients with coronary artery disease who were treated in our hospital from April 2017 to April 2018 were randomly selected as the study subjects. According to the random principle, they were divided into three groups: A, B, and C. 40 patients in each group were given conventional treatment in group A.Patients in groups B and C were treated with rosuvastatin 5 mg/d and 10 mg/d, respectively. The interventional therapy was observed.The effect of different rosuvastatin doses on blood lipids and safety after surgery. Results After treatment, the therapeutic effects of TC and LDL-C in both groups B and C were better than those in group A and before treatment.The difference was statistically significant(P<0.05). There was no significant difference in TG and HDL-C levels between the three groups of patients before treatment(P>0.05). The incidence of ischemic events was lower in group B and C than in group A, and the difference was statistically significant(P<0.05). The incidence of adverse reactions in group B was higher than that in group A, and the difference was not statistically significant(P>0.05). The incidence of adverse reactions in group C was higher than that in group A, and the difference was statistically significant(P<0.05). Conclusion The use of rosuvastatin in the treatment of patients with coronary heart disease after interventional therapy can effectively improve the level of TC, LDL-C, and reduce the incidence of ischemic events;as the dose of rosuvastatin increases,the effect on the blood lipid changes is also greater and the risk of adverse reactions increases.